

Industry Therapeutic Update from Sanofi Medical

Spotlight on CIDP:

Evolving Perspectives
On Disease Management

**Navigating Management Challenges,
Scientific Progress, and Practical
Patient Care**

Wednesday, April 22, 2026

11:45 AM – 12:45 PM CDT

McCormick Place,
West Building, Room 470



Agenda

Welcome and Introduction: Unmet Needs in CIDP

David Cornblath, MD

Advancing Treatment Goals in a Highly Heterogeneous Disease

Richard Lewis, MD

Evolving CIDP Management with Insights from Pathophysiology

Jeffrey Allen, MD

Panel Discussion and Q&A: Bridging Science and Practice in CIDP Care – Shaping the Future

All speakers

Summary and Meeting Close

David Cornblath, MD



David Cornblath, MD

Johns Hopkins University
School of Medicine,
Baltimore, USA



Richard Lewis, MD

Cedars-Sinai
Medical Center,
Los Angeles, USA



Jeffrey Allen, MD

University of Minnesota,
Minneapolis, USA

Join leading experts in CIDP as they spotlight advances shaping the future of care.

This dynamic symposium will address critical unmet needs, including diagnostic complexity, disease heterogeneity, and current therapeutic limitations. Discover how emerging insights into pathobiology, immune mechanisms, and biomarkers could pave the future path for CIDP management.

Be part of an interactive panel discussion designed to bridge cutting-edge science with clinical practice—offering practical perspectives to help improve outcomes for people living with CIDP.

Join us at the 2026 AAN Annual Meeting
for an **exciting and interactive session.**





David Cornblath, MD

Johns Hopkins University
School of Medicine,
Baltimore, USA

Dr. David Cornblath received his medical degree from Case Western Reserve University and completed his internship in medicine at University Hospitals in Cleveland, Ohio and a residency in neurology and clinical fellowship at the Hospital of the University of Pennsylvania. He joined the Faculty of Neurology at Johns Hopkins where he is now Professor Emeritus. Dr. Cornblath has published on Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis, neuromuscular diseases associated with HIV infection, diabetic neuropathy, and painful neuropathies. He is a co-inventor of the Total Neuropathy Score[®]. He is a past Editor-in-Chief of the JPNS, the official Journal of the Peripheral Nerve Society.

Richard Lewis, MD

Cedars-Sinai
Medical Center,
Los Angeles, USA



Dr Richard Lewis is a Professor of Neurology at Cedars-Sinai since 2012 and has been Director of Electromyography and Neuromuscular Medicine.

He earned his medical degree from Virginia Commonwealth University Health System in 1974. He completed his residency at the Hospital of the University of Pennsylvania in 1978 and has been faculty at Penn, University of Connecticut, Eastern Virginia Medical Center and was Associate Clinical Chair of Neurology at Wayne State University from 1993–2012. He was President of the Peripheral Nerve Society from 2022–2024.

His research is primarily on peripheral neuropathies and electromyography with a focus on demyelinating neuropathies.

He has published extensively on inflammatory neuropathies including Guillian–Barre Syndrome and chronic inflammatory demyelinating polyneuropathy as well as on inherited neuropathies such as Charcot–Marie–Tooth disease.



Jeffrey Allen, MD

University of Minnesota,
Minneapolis, USA

Dr Jeffrey Allen is a Professor in the Department of Neurology at the University of Minnesota, Minneapolis, MN.

He completed his neurology residency training at Tufts University, and neuromuscular fellowship at Harvard. Dr Allen's research has focused on defining the clinical and diagnostic boundaries of the inflammatory neuropathies, as well as investigating treatments for those disorders. The inflammatory neuropathies of interest include Guillian-Barre Syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.

He serves as chairman of GBS/CIDP Foundation International Global Medical Advisory Board, and is involved with the Peripheral Nerve Society, Inflammatory Neuropathy Consortium, American Academy of Neurology and American Academy of Neuromuscular and Electrodiagnostic Medicine.

Scan the QR code to share
your feedback on the
Industry Therapeutic Update
from Sanofi Medical.



All responses will be anonymous.

AAN, American Academy of Neurology; CIDP, chronic inflammatory demyelinating polyneuropathy; CDT, central daylight time; GBS, Guillian-Barre Syndrome; HIV, human immunodeficiency virus; JPNS, Journal of the Peripheral Nerve Society. This program is NOT accredited for continuing medical education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2026 AAN Annual Meeting. This is a non-promotional medical symposium sponsored by Sanofi. The content was developed by Sanofi in consultation with scientific experts for scientific exchange purposes and is not eligible for CME credits. ©2026 Sanofi. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate. 450 Water Street, Cambridge, MA 02141. <https://www.sanofi.com/en/contact>.
MAT-GLB-2601315 - 1.0 - 04/2026

sanofi